Search the Newsreel

Lobbying Update: $40,000 of AMYLYX PHARMACEUTICALS lobbying was just disclosed

AMYLYX PHARMACEUTICALS (AMLX) recently disclosed $40,000 in lobbying expenditures for Q2 2026, focusing on "rare disease and access to innovation." The article also details recent insider trading activity, with more sales than purchases, and provides an overview of institutional investor movements and current analyst …

Trade Alert: Chief Legal Officer & General Counsel Of Amylyx Pharmaceuticals Gina Mazzariello Has Sold Stock

Gina Mazzariello, Chief Legal Officer & General Counsel of Amylyx Pharmaceuticals, recently sold US$539k worth of stock at US$17.96 per share, reducing her holding by 47%. This marks the largest insider sale in the last year for the company. While insiders own a healthy …

Is Amylyx Pharmaceuticals (AMLX) A Bargain Following Russell Index Removals?

Index Exit and Early ALS Data Could Be A Game Changer For Amylyx Pharmaceuticals (AMLX)

AMLX Forecast — Price Target — Prediction for 2027

Amylyx Pharmaceuticals (AMLX) Q1 2026 Earnings: EPS Misses Estimates as R&D Focus Continues - Management Tone Analysis

A Look At Amylyx Pharmaceuticals (AMLX) Valuation After Its Recent Share Price Rebound

Is It Too Late To Consider Amylyx Pharmaceuticals (AMLX) After A 220% One Year Surge?

Amylyx Pharmaceuticals Q1 Earnings Call Highlights

Amylyx (AMLX) -7.8%: Earnings Show $0 Revenue, Shelf Filing Adds Dilution Fear

Here's Why We're A Bit Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Situation

Amylyx Pharmaceuticals (AMLX) Stock Price, News & Analysis

Amylyx Pharmaceuticals (AMLX) Stock News